Target Name: RNF115
NCBI ID: G27246
Other Name(s): E3 ubiquitin-protein ligase RNF115 | RABRING7 | Ring finger protein 115 | Zinc finger protein 364 | ZNF364 | RING-type E3 ubiquitin transferase RNF115 | rab7-interacting RING finger protein | rabring 7 | RING finger protein 115 | OTTHUMP00000015602 | ZFP364 | zinc finger protein 364 | RN115_HUMAN | Rabring 7 | BCA2 | E3 ubiquitin-protein ligase RNF115-like | ring finger protein 115

Unlocking the Potential of RNF115: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:

RNF115, an essential enzyme in the ubiquitin-protein ligase pathway, has been identified as a potential drug target and biomarker for the treatment of chronic pain. This article summarizes the current understanding of RNF115, its functions, and its potential as a drug target in the context of chronic pain.

Introduction:

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can lead to significant morbidity and quality of life. While several medications have been developed to alleviate chronic pain, the majority of patients continue to experience ongoing symptoms . Therefore, there is a need for new treatments that can effectively manage chronic pain.

RNF115: A Potential Drug Target and Biomarker

The ubiquitin-protein ligase pathway is a critical molecular mechanism involved in the regulation of protein function and stability. This pathway is composed of various enzymes, including RNF115, which plays a crucial role in the degradation of ubiquitin-protein ligands. RNF115 is a 26 kDa protein that consists of 215 amino acid residues. It is expressed in various tissues, including the brain, spleen, and pancreas, and its function is essential for the maintenance of cellular homeostasis.

RNF115 has been shown to participate in the regulation of protein degradation, which is a critical process that helps maintain the stability of cellular proteins and reduces the risk of protein-related diseases. In addition, RNF115 has been implicated in the development and maintenance of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting RNF115 may provide new insights into the treatment of chronic pain.

Potential Drug Targets:

Several drug targets have been identified that can potentially interact with RNF115. One of these targets is the serine/threonine kinase Pyk6, which is known to interact with RNF115 and enhance its catalytic activity. Pyk6 has been shown to play a role in the regulation of pain perception and neuroinflammation, making it a potential target for the treatment of chronic pain.

Another potential drug target is the protein kinase Ago1, which is known to interact with RNF115 and regulate its activity. Ago1 has been implicated in the regulation of pain signaling and neurotransmitter release, making it a potential target for the treatment of chronic pain.

Biomarkers:

RNF115 has also been identified as a potential biomarker for the assessment of chronic pain. The degradation of ubiquitin-protein ligands by RNF115 has been shown to be affected by various factors, including pain intensity, pain duration, and pain modalities. Therefore , the levels of RNF115 may be an indicator of chronic pain and could be used as a biomarker for the assessment of pain severity and duration.

Conclusion:

RNF115 is an essential enzyme involved in the regulation of protein degradation and has been implicated in the development and maintenance of various diseases. Its potential as a drug target and biomarker make it an attractive target for the development of new treatments for chronic pain. Further research is needed to fully understand the functions of RNF115 in pain regulation and to develop effective treatments.

Protein Name: Ring Finger Protein 115

Functions: E3 ubiquitin-protein ligase that mediates E2-dependent, 'Lys-48'- and/or 'Lys-63'-linked polyubiquitination of substrates and may play a role in diverse biological processes. Through their polyubiquitination, may play a role in the endosomal trafficking and degradation of membrane receptors including EGFR, FLT3, MET and CXCR4

More Common Targets

RNF121 | RNF122 | RNF123 | RNF125 | RNF126 | RNF126P1 | RNF128 | RNF13 | RNF130 | RNF133 | RNF135 | RNF138 | RNF138P1 | RNF139 | RNF139-DT | RNF14 | RNF141 | RNF144A | RNF144B | RNF145 | RNF146 | RNF148 | RNF149 | RNF150 | RNF151 | RNF152 | RNF157 | RNF157-AS1 | RNF165 | RNF166 | RNF167 | RNF168 | RNF169 | RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1